Bayer (BAYRY) announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency ("EMA") for its pipeline candidate elinzanetant. The MAA is seeking approval of the candidate for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or adjuvant endocrine therapy. Image Source: Zacks Investment Research Year to date, shares of Bayer have lost 21.7% against the industry's growth of 20.6%. BAYRY's Progress Wit ...